Figure 1.
Waterfall plot showing the change in SUVmax in the head and neck region from baseline to post-mAb therapy per study arm for the safety population patients. The dotted line at –25% represents the EORTC recommended cut-off between the lower level of stable metabolic disease and the upper level of metabolic response. Centrally read PET scans were not available for four patients from the 700-mg imgatuzumab arm, six patients from the 1400-mg imgatuzumab arm, and 10 cetuximab patients. This was due to either missing baseline/post-mAb therapy PET scans, large differences in baseline and post-mAb therapy uptake times, or because the PET scans were done at non-qualified sites. EORTC, European Organization for Research and Treatment of Cancer; mAb, monoclonal antibody; PET, positron emission tomography; SUVmax, maximum standardized uptake value.